For the quarter ended March 2026, Clorox (CLX) reported revenue of $1.67 billion, up 0.1% over the same period last year. EPS came in at $1.64, compared to $1.45 in the year-ago quarter.
The reported revenue represents a surprise of +1.36% over the Zacks Consensus Estimate of $1.65 billion. With the consensus EPS estimate being $1.48, the EPS surprise was +10.83%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Clorox performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Organic sales growth - International: 2% versus the four-analyst average estimate of 6.4%.
- Organic sales growth - Lifestyle: -9% compared to the -2.3% average estimate based on four analysts.
- Organic sales growth - Household: 3% compared to the -3.1% average estimate based on four analysts.
- Organic sales growth (non-GAAP): -1% compared to the -0.9% average estimate based on four analysts.
- Net Sales- Health and Wellness: $629 million compared to the $621.26 million average estimate based on four analysts. The reported number represents a change of -0.2% year over year.
- Net Sales- International: $285 million versus the four-analyst average estimate of $281.06 million. The reported number represents a year-over-year change of +8.4%.
- Net Sales- Lifestyle: $277 million compared to the $299.12 million average estimate based on four analysts. The reported number represents a change of -9.5% year over year.
- Net Sales- Household: $482 million versus the four-analyst average estimate of $454.27 million. The reported number represents a year-over-year change of +2.8%.
- Income before income taxes- Health and Wellness: $158 million compared to the $164.16 million average estimate based on two analysts.
- Income before income taxes- Corporate and Other: $-32 million compared to the $-53.39 million average estimate based on two analysts.
- Income before income taxes- International: $36 million versus the two-analyst average estimate of $29.66 million.
- Income before income taxes- Lifestyle: $60 million versus $58.91 million estimated by two analysts on average.
View all Key Company Metrics for Clorox here>>>
Shares of Clorox have returned -9.1% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>The Clorox Company (CLX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
